Earnings ·
Janux Therapeutics reports $21.6M Q3 net loss and $945.7M cash balance
JANXJanux Therapeutics, Inc.
Janux Therapeutics reported a net loss of $21.6 million for the quarter ended September 30, 2026, compared to a $24.3 million loss in the prior-year period. Research and development expenses decreased to $30.6 million from $34.6 million, while general and administrative costs fell to $10.0 million from $10.6 million. The company ended the quarter with $945.7 million in cash, cash equivalents, and short-term investments. Clinically, Janux dosed the first patient in a Phase 1 study of JANX013 in combination with JANX007 for metastatic castration-resistant prostate cancer and continues enrollment of JANX014. Initial data from the healthy-volunteer study of JANX011 will be presented on November 9, 2026. Janux Therapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for oncology and autoimmune diseases.